• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Deciphera Pharmaceuticals Inc. (Amendment)

    2/12/24 5:32:15 PM ET
    $DCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DCPH alert in real time by email
    SC 13G/A 1 e619254_sc13ga-dp.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. 1) *

     

    Deciphera Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    24344T101

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    (Page 1 of 9 Pages)

     

    ----------

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

           

    CUSIP No. 24344T101 13G Page 2 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Mgmt, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    5,788,024 (1)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    5,788,024 (1)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,788,024 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.19%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

    __________________

    (1) Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

        

    CUSIP No. 24344T101 13G Page 3 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Management Company, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    5,788,024 (2)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    5,788,024 (2)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,788,024 (2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.19%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

    __________________

    (2) Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment advisor.

         

    CUSIP No. 24344T101 13G Page 4 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Partners, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    5,788,024

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    5,788,024

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,788,024

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.19%

    12.

    TYPE OF REPORTING PERSON*

     

    PN 

      

    CUSIP No. 24344T101 13G Page 5 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    James E. Flynn

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    5,788,024 (3)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    5,788,024 (3)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,788,024 (3)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.19%

    12.

    TYPE OF REPORTING PERSON*

     

    IN

    __________________

    (3) Comprised of shares of common stock held by Deerfield Partners, L.P.

         

    CUSIP No. 24344T101 13G Page 6 of 9

     

    Item 1(a). Name of Issuer:
       
     

    Deciphera Pharmaceuticals, Inc.

       
    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    200 Smith Street,

    Waltham, MA 02451

       
    Item 2(a). Name of Person Filing:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.

       
    Item 2(b). Address of Principal Business Office, or if None, Residence:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

       
    Item 2(c). Citizenship:
       
     

    Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships;

     

    James E. Flynn – United States citizen

       
    Item 2(d). Title of Class of Securities:
       
     

    Common Stock, par value $0.01 per share

       
    Item 2(e). CUSIP Number:
       
     

    24344T101

         
    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

       
    (a) ☐

    Broker or dealer registered under Section 15 of the Exchange Act.

         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) ☐

    Insurance company as defined in Section 3(a)(19) of the Exchange Act.

         
    (d) ☐

    Investment company registered under Section 8 of the Investment Company Act.

         
    (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

         
    (g) ☐

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

         

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

         
    (i) ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    CUSIP No. 24344T101 13G Page 7 of 9

     

         
    (j) ☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

    Item 4. Ownership.
           

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

           
    (a) Amount beneficially owned**:  
           
     

    Deerfield Mgmt, L.P. - 5,788,024 shares

    Deerfield Management Company, L.P. - 5,788,024 shares

    Deerfield Partners, L.P. - 5,788,024 shares

    James E. Flynn – 5,788,024 shares

           
    (b) Percent of class**:  
           
     

    Deerfield Mgmt, L.P. – 7.19%

    Deerfield Management Company, L.P. – 7.19%

    Deerfield Partners, L.P. – 7.19%

    James E. Flynn – 7.19%

           
    (c) Number of shares as to which such person has**:  
           
      (i) Sole power to vote or to direct the vote: All Reporting Persons - 0
           
      (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 5,788,024

    Deerfield Management Company, L.P. - 5,788,024

    Deerfield Partners, L.P. - 5,788,024

    James E. Flynn – 5,788,024

           
      (iii)

    Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0
           
      (iv)

    Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 5,788,024

    Deerfield Management Company, L.P. - 5,788,024

    Deerfield Partners, L.P. - 5,788,024

    James E. Flynn – 5,788,024

      

    **See footnotes on cover pages which are incorporated by reference herein.

     

    CUSIP No. 24344T101 13G Page 8 of 9

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☐.

       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

       

    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       

    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      See Exhibit B
       
    Item 9. Notice of Dissolution of Group.
       

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A
       
    Item 10. Certifications.
       

    "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

     

    CUSIP No. 24344T101 13G Page 9 of 9

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    Date: February 12, 2024

     

     

     

     

    Exhibit List

     

    Exhibit A. Joint Filing Agreement.

     

    Exhibit B. Item 8 Statement.

     

    Exhibit C. Power of Attorney (1).

     

    (1) Power of Attorney previously filed as Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.

     

     

     

     

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock, par value $0.01 per share, of Deciphera Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

     

     

     

    Exhibit B

     

    Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

     

     

     

     

    Get the next $DCPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DCPH

    DatePrice TargetRatingAnalyst
    11/20/2023$14.00Neutral
    JP Morgan
    10/30/2023$23.00Neutral → Overweight
    Piper Sandler
    8/10/2023$14.00 → $20.00Hold → Buy
    Stifel
    1/4/2023$22.00Neutral → Buy
    Guggenheim
    8/29/2022$25.00Outperform
    Cowen
    8/5/2022$23.00Mkt Perform → Mkt Outperform
    JMP Securities
    2/28/2022$11.00 → $6.00Equal-Weight → Underweight
    Barclays
    12/1/2021$25.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DCPH
    Leadership Updates

    Live Leadership Updates

    See more
    • The Week in Canadian Press Releases: 10 Stories You Need to See

      A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Oct. 6, 2023 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that

      10/6/23 6:18:00 AM ET
      $DCPH
      $SLF
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Life Insurance
      Finance
    • Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer

      — Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol, Ph.D., continues as Board Member — Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Company's Founder, Executive Vice President, and Chief Scientific Officer, Daniel L. Flynn, Ph.D., will retire effective September 5, 2023 and will transition to a role as Senior Advisor to the Company. Dashyant Dhanak, Ph.D., has been appointed Executive Vice President and Chief Scientific Officer effective September 5, 2023. Dr. Dhanak brings over 30 year

      8/3/23 4:15:00 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer

      Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership experience to the role, and her responsibilities will include developing and leading the Company's business development efforts as well as supporting corporate strategy initiatives. "We are thrilled to welcome Kelley to our executive team as Chief Business Officer. Kelley has extensive leadership experience in pharmaceutical and biotechnology companies with a proven track record of building value through business development and strategic partnerships," said Steve Hoerter, President and Ch

      6/16/22 7:00:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

      OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, CEO: Steven L. Hoerter, ", Deciphera", ))) for US$25.60 per share (total amount of approximately US$2.4 billion) net to the seller in cash, without interest thereon and less any applicable withholding taxes, through its wholly owned subsidiary, Topaz Merger Sub, Inc. ("Merger Sub"), established in the State of Delaware, United S

      6/11/24 8:30:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

      – MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in the Second Quarter of 2024 and Marketing Authorisation Application (MAA) in the Third Quarter of 2024 – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company's MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being

      6/3/24 7:00:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

      OSAKA, Japan, April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, Chief Executive Officer: Steven L. Hoerter, ", Deciphera", ))) today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO (the "Acquisit

      4/30/24 7:00:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    SEC Filings

    See more
    • SEC Form 15-12G filed by Deciphera Pharmaceuticals Inc.

      15-12G - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)

      6/21/24 8:02:56 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Deciphera Pharmaceuticals Inc.

      EFFECT - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)

      6/14/24 12:15:03 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Deciphera Pharmaceuticals Inc.

      S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)

      6/11/24 5:18:25 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Deciphera Pharmaceuticals with a new price target

      JP Morgan resumed coverage of Deciphera Pharmaceuticals with a rating of Neutral and set a new price target of $14.00

      11/20/23 7:26:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deciphera Pharmaceuticals upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Deciphera Pharmaceuticals from Neutral to Overweight and set a new price target of $23.00

      10/30/23 11:51:39 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deciphera Pharmaceuticals upgraded by Stifel with a new price target

      Stifel upgraded Deciphera Pharmaceuticals from Hold to Buy and set a new price target of $20.00 from $14.00 previously

      8/10/23 6:19:16 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Medical Officer Sherman Matthew L was granted 34,157 shares and returned 72,029 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)

      6/11/24 9:02:09 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Kelly Thomas Patrick was granted 34,157 shares and returned 72,029 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)

      6/11/24 8:56:07 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Development Officer Pitman Jama was granted 20,163 shares and returned 53,951 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)

      6/11/24 8:51:39 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    Financials

    Live finance-specific insights

    See more
    • Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

      OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, CEO: Steven L. Hoerter, ", Deciphera", ))) for US$25.60 per share (total amount of approximately US$2.4 billion) net to the seller in cash, without interest thereon and less any applicable withholding taxes, through its wholly owned subsidiary, Topaz Merger Sub, Inc. ("Merger Sub"), established in the State of Delaware, United S

      6/11/24 8:30:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

      OSAKA, Japan, April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH, Chief Executive Officer: Steven L. Hoerter, ", Deciphera", ))) today announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO (the "Acquisit

      4/30/24 7:00:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results

      – Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 – – Expects to Submit NDA for Vimseltinib in the Second Quarter of 2024 and MAA in the Third Quarter of 2024 in Tenosynovial Giant Cell Tumor (TGCT) – – Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study in 2L GIST Patients with Mutations in KIT Exon 11+17/18 Published in Nature Medicine; Final Overall Survival (OS) Results from INTRIGUE Study in 2L GIST Patients Presented at ASCO GI – – Cash Expected to Fund Operating and Capital Expenditures into the Second Half of 2026 – Deciphera

      2/6/24 7:00:00 AM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DCPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Deciphera Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)

      2/14/24 4:26:20 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Deciphera Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)

      2/14/24 4:06:14 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Deciphera Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Deciphera Pharmaceuticals, Inc. (0001654151) (Subject)

      2/14/24 2:26:21 PM ET
      $DCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care